Premium
Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort
Author(s) -
Schoretsanitis Georgios,
Dubath Céline,
Grosu Claire,
Piras Marianna,
Laaboub Nermine,
Ranjbar Setareh,
Ansermot Nicolas,
Crettol Séverine,
Vandenberghe Frederik,
Gamma Franziska,
Gunten Armin,
Plessen Kerstin Jessica,
Seifritz Erich,
Conus Philippe,
Eap Chin B.
Publication year - 2022
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/bcpt.13715
Subject(s) - olanzapine , medicine , interquartile range , weight gain , blood pressure , odds ratio , prospective cohort study , endocrinology , gastroenterology , body weight , schizophrenia (object oriented programming) , psychiatry
Metabolic abnormalities have been associated with olanzapine treatment. We assessed if olanzapine has dose‐dependent effects on metabolic parameters with changes for weight, blood pressure, lipid and glucose profiles being modelled using linear mixed‐effects models. The risk of metabolic abnormalities including early weight gain (EWG) (≥5% during first month) was assessed using mixed‐effects logistic regression models. In 392 olanzapine‐treated patients (median age 38.0 years, interquartile range [IQR] = 26.0–53.3, median dose 10.0 mg/day, IQR = 5.0–10.0 for a median follow‐up duration of 40.0 days, IQR = 20.7–112.2), weight gain was not associated with olanzapine dose ( p = 0.61) although it was larger for doses versus ≤10 mg/day (2.54 ± 5.55 vs. 1.61 ± 4.51% respectively, p = 0.01). Treatment duration and co‐prescription of >2 antipsychotics, antidepressants, benzodiazepines and/or antihypertensive agents were associated with larger weight gain ( p < 0.05). Lower doses were associated with increase in total and HDL cholesterol and systolic and diastolic blood pressure ( p < 0.05), whereas higher doses were associated with glucose increases ( p = 0.01). Patients receiving >10 mg/day were at higher EWG risk (odds risk: 2.15, 1.57–2.97). EWG might be prominent in high‐dose olanzapine‐treated patients with treatment duration and co‐prescription of other medications being weight gain moderators. The lack of major dose‐dependent patterns for weight gain emphasizes that olanzapine‐treated patients are at weight gain risk regardless of the dose.